TianYi

Nanjing Tianyi Biotechnology (also known as Tianyi Bioscience) is an innovative biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics for oncology. As a wholly-owned subsidiary of Nanjing PharmaBlock, the company leverages its parent's extensive chemical building block library and medicinal chemistry expertise to design and optimize proprietary drug candidates. Its lead program, TY-011, is a multi-kinase inhibitor targeting Aurora kinases A and B and VEGFR2, demonstrating potent antitumor activity in preclinical models of solid tumors. Tianyi Biotechnology aims to bridge the gap between advanced chemical innovation and clinical application, with a primary focus on addressing unmet needs in gastric cancer treatment.